uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Karolinska Inst, Dept Pathol & Oncol, S-17176 Stockholm, Sweden.;Univ Hosp, Canc Ctr Karolinska R8 3, Stockholm, Sweden..
Karolinska Inst, Dept Pathol & Oncol, S-17176 Stockholm, Sweden.;Univ Hosp, Canc Ctr Karolinska R8 3, Stockholm, Sweden..
Univ Hosp, Canc Ctr Karolinska R8 3, Stockholm, Sweden.;Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.;Karolinska Inst, Dept Biosci & Nutr, S-17176 Stockholm, Sweden..
Karolinska Inst, Dept Pathol & Oncol, S-17176 Stockholm, Sweden.;Univ Hosp, Canc Ctr Karolinska R8 3, Stockholm, Sweden..
Show others and affiliations
2016 (English)In: Clinical Cancer Research, ISSN 1078-0432, E-ISSN 1557-3265, Vol. 22, no 10, 2417-2426 p.Article in journal (Refereed) PublishedText
Abstract [en]

Purpose: The ability of vascular genes to provide treatment predictive information in breast cancer patients remains unclear. As such, we assessed the expression of genes representative of normal endothelial microvasculature (MV) in relation to treatment-specific patient subgroups. Experimental Design: We used expression data from 993 breast tumors to assess 57 MV genes (summarized to yield an MV score) as well as the genomic grade index (GGI) and PAM50 signatures. MV score was compared with CD31 staining by correlation and gene ontology (GO) analysis, along with clinicopathologic characteristics and PAM50 subtypes. Uni-, multivariate, and/or t-test analyses were performed in all and treatment-specific subgroups, along with a clinical trial cohort of patients with metastatic breast cancer, seven of whom received antiangiogenic therapy. Results: MV score did not correlate with microvessel density (correlation = 0.096), but displayed enrichment for angiogenic GO terms, and was lower in Luminal B tumors. In endocrine-treated patients, a high MV score was associated with decreased risk of metastasis [HR 0.58; 95% confidence interval (CI), 0.38-0.89], even after adjusting for histologic grade, but not GGI or PAM50. Subgroup analysis showed the prognostic strength of the MV score resided in low genomic grade tumors and MV score was significantly increased in metastatic breast tumors after treatment with sunitinib + docetaxel (P = 0.031). Conclusions: MV score identifies two groups of better and worse survival in low-risk endocrine-treated breast cancer patients. We also show normalization of tumor vasculature on a transcriptional level in response to an angiogenic inhibitor in human breast cancer samples.

Place, publisher, year, edition, pages
2016. Vol. 22, no 10, 2417-2426 p.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-297782DOI: 10.1158/1078-0432.CCR-15-1691ISI: 000375839200014PubMedID: 26769751OAI: oai:DiVA.org:uu-297782DiVA: diva2:943625
Funder
Swedish Cancer SocietySwedish Research Council, 524-2014-4483Swedish Research Council, 521-2014-2057Forte, Swedish Research Council for Health, Working Life and Welfare, 2014-1962Knut and Alice Wallenberg FoundationAstraZeneca
Available from: 2016-06-28 Created: 2016-06-28 Last updated: 2016-06-28Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
He, LiqunBetsholtz, Christer
By organisation
Vascular Biology
In the same journal
Clinical Cancer Research
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 57 hits
ReferencesLink to record
Permanent link

Direct link